CATAPULT SPORTS LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT

CAT - CATAPULT SPORTS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 0.32
Index: ASX300 | ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.10

03 Sep
2026

-0.060

OPEN

$3.15

-1.90%

HIGH

$3.18

1,428,689

LOW

$3.10

TARGET
$5.134 65.6% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY27
Forecast		 FY28
Forecast
EPS (cps) - 6.2 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-13.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx101.6
Net Operating Cash Flow xxxxxxxxxxxxxxx57.3 M
Net Profit Margin xxxxxxxxxxxxxxx-17.03 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-16.41 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.73 %
Return on Assets xxxxxxxxxxxxxxx-9.79 %
Return on Equity xxxxxxxxxxxxxxx-16.41 %
Return on Total Capital xxxxxxxxxxxxxxx-14.18 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx36.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx164 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx78 M
Price To Book Value xxxxxxxxxxxxxxx3.17

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx56.7 M
Capex % of Sales xxxxxxxxxxxxxxx26.60 %
Cost of Goods Sold xxxxxxxxxxxxxxx214 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

25/05/2026

1

Buy

$5.40

74.19%

Catapult Sports posted a FY26 result that augurs well for the medium-term targets, Morgans observes, with management EBITDA of US$25m beating estimates. Operating leverage is now evident to the broker, amid a 41% incremental margin.

The company closed the year with US$53.5m in cash on the balance sheet and no debt. The statutory loss of -US$24m has widened, with the deterioration largely non-cash and acquisition-related.

The broker makes some adjustments to medium-term estimates which results in -6%-8% downgrades to management EBITDA over FY27-FY29. Target is lowered to $5.40 from $5.55 while a Buy rating is retained.

FORECAST
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.89 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

22/07/2026

1

Initiation of coverage with Buy

$4.25

37.10%

Moelis initiates coverage on Catapult Sports with a Buy rating and a $4.25 target price.

The analyst notes the sports technology market is expanding at a 15% compound annual growth rate, driven by professional sports commercialisation, athlete optimisation, and AI-driven coaching tools.

Catapult maintains a leading first-mover advantage in wearables, the report highlights, generating valuable longitudinal performance datasets and high customer retention exceeding 96%.

Strategic acquisitions, including IMPECT, enhance the company's tactics, video, and scouting capabilities whilst opening cross-selling opportunities to expand average contract value.

Operating leverage from a fixed R&D and general administrative cost base is expected to drive long-term margin expansion as subscription revenues scale.

FORECAST
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.73 cents.
Moelis forecasts a full year FY28 dividend of 0.00 cents and EPS of 5.23 cents.
Access Extra Coverage Research History >

CAT STOCK CHART

FNArena News on CAT

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jul 30, 2026

Jul 30 2026 - Daily Market Reports
3
In Brief: Catapult Sports, Hazer Group & ResMed

Jul 24 2026 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Jul 22, 2026

Jul 22 2026 - Daily Market Reports
5
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals